With deep expertise in chemistry and structure-based drug discovery, Nuvalent is creating precisely targeted therapies for patients with cancer.
The company designs innovative small molecules that precisely inhibit clinically proven kinase targets to address the dual challenges of resistance and selectivity.
Nuvalent has assembled a world-class team with deep expertise in structure-based drug discovery, oncology drug development, and building new companies.